Health and Fitness Health and Fitness
Tue, April 3, 2012
[ Tue, Apr 03rd 2012 ] - Market Wire
EntreMed Appoints Interim CEO
Mon, April 2, 2012
Sun, April 1, 2012
Sat, March 31, 2012
Fri, March 30, 2012
Thu, March 29, 2012
Wed, March 28, 2012
Tue, March 27, 2012
Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
Wed, March 21, 2012

Optimer Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. e-11th-annual-needham-healthcare-conference.html
Published in Health and Fitness on Wednesday, March 28th 2012 at 5:06 GMT by Market Wire   Print publication without navigation


Optimer Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference -- SAN DIEGO, March 28, 2012 /PRNewswire/ --

Optimer Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference

[ ]

SAN DIEGO, March 28, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) today announced that the Company will present at the 11th Annual Needham Healthcare Conference on Tuesday, April 3 at 3:20 p.m. Eastern Time in New York, NY.

(Logo:  [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ])

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at [ www.optimerpharma.com ].  Replays of the presentation will be available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736
[ Dwalsey@optimerpharma.com ]

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
[ Jason@canalecomm.com ]

SOURCE Optimer Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.optimerpharma.com ]


Publication Contributing Sources